Loading…

Loading grant details…

Active HORIZON European Commission

Causes and consequences of aberrant mRNA translation in cancer

€2.5M EUR

Funder European Commission
Recipient Organization Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
Country Netherlands
Start Date Sep 01, 2024
End Date Aug 31, 2029
Duration 1,825 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101141245
Grant Description

Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes.

Tumor cells enhance or inhibit the production of key amino acid metabolites to stimulate oncogenesis and suppress anti-tumor activity. A key player in this battle is tryptophan.

Activated T cells secrete interferon-, which upregulates IDO1 enzyme to catabolize tryptophan to kynurenine in target tumor cells. While kynurenine suppresses T-cell function, its production limits tryptophan availability in tumor cells.

Importantly, as tumor cells almost invariably deregulate mRNA translation to promote proliferation and metastasis, the consequences of tryptophan shortage are major.

It provokes aberrant mRNA translation at tryptophan codons, resulting in ribosomal frameshifting and tryptophan to phenylalanine (W>F) codon reassignments (substitutants).

This aberrant mRNA translation alters protein function and enriches the landscape of neoepitopes at the surface of tumor cells.

Based on these observations, I hypothesize here that the detection of aberrant proteins in cancer specimens can reveal additional key processes of cancer progression beyond tryptophan that can be utilized for cancer therapy.

To explore this exciting new idea, I designed three work packages (WPs):WP1 will expand the landscape of aberrant mRNA translation in cancer and link them to cancerous events. Preliminary results pinpoint arginine, histidine, and leucine.

WP2 will generate reporter assays, set up functional genetic screens, and identify, validate, and explore key regulators of aberrant mRNA translation.WP3 will study the functional consequences of aberrant mRNA translation, and introduce novel therapeutic concepts.Altogether, this proposal will employ our recent discoveries of aberrant mRNA translation during periods of amino acid shortages to explore novel interplays between cancers and their suppressive microenvironment, and utilize this new knowledge for cancer therapy.

All Grantees

Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant